We are leading the way by connecting access, innovation, and experience.
By 2026, the cost of gene therapy drugs is expected to reach more than $13.9 billion.1 If health plans cannot afford to cover these drugs, the patients that need them will not have access.
Embarc Benefit Protection
The Embarc Benefit Protection solution offers an answer to this impending crisis. It brings together the health services, medical management, and specialty pharmacy expertise of Cigna, eviCore, Accredo, and Express Scripts. This solution helps shield health plans and customers from the high cost of breakthrough gene therapy drugs and helps to ensure access for those who need them.
The solution includes:
- Luxturna® (voretigene neparvovec-rzyl): The first FDA-approved prescription gene therapy for people with inherited retinal disease
- Zolgensma® (onasemnogene abeparvovec-xioi): A gene therapy for children under 2 years old with spinal muscular atrophy
- Additional therapies may be added in the future
Like our recent advances with our Patient Assurance ProgramSM and digital health formulary, the Embarc Benefit Protection solution is another great example of what our combined company can do for our clients and customers. Employers, health plans, and unions can have the peace of mind that comes from being better protected against the high costs associated with new breakthrough therapies.
1 EvaluatePharma, Evaluate Ltd, London UK. www.evaluate.com Accessed 5/1/2020.
Product availability may vary by location and plan type and is subject to change. For costs and details contact a Cigna representative.
All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including eviCore healthcare MSI, LLC (d/b/a/ eviCore healthcare), Express Scripts, Inc., Accredo Health Group, Inc., or their affiliates. Luxturna is the registered trademark of Spark Therapeutics, Inc. and Zolgensma is the registered trademark of AveXis, Inc.
© 2020 Cigna. Some content provided under license